Published in
American Society of Hematology, Blood, 14(132), p. 1507-1518
DOI: 10.1182/blood-2018-01-824607
Links
Tools
North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
Journal article published in 2018 by
Urvi A. Shah 
,
Elaine Y. Chung,
Orsi Giricz,
Kith Pradhan,
Tushar D. Bhagat ,
Keisuke Kataoka,
Shanisha Gordon-Mitchell,
Gaurav S. Choudhary,
Ancy Joseph ,
Yun Mai,
Ronald Rice,
Nadege Gitego,
Crystall Parrish,
Yongqiang Wei,
Matthias Bartenstein
and other authors.
,
Elaine Y. Chung,
Orsi Giricz,
Kith Pradhan,
Tushar D. Bhagat ,
Keisuke Kataoka,
Shanisha Gordon-Mitchell,
Gaurav S. Choudhary,
Ancy Joseph ,
Yun Mai,
Ronald Rice,
Nadege Gitego,
Crystall Parrish,
Yongqiang Wei,
Matthias Bartenstein
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points North American ATLL has a distinct genomic landscape with a high frequency of prognostic epigenetic mutations, including EP300 mutations. ATLL samples with mutated EP300 have compromised p53 function and are selectively sensitive to decitabine treatment.